Thrombolytic therapy for acute myocardial infarction.
Numerous factors must be considered when determining the formulary status of thrombolytic agents for the treatment of acute myocardial infarction. Defined treatment options, predicted outcomes, and the economic consequences of this disorder continue to evolve from clinical trials. Pharmacists have a major role in delivering patient care, with responsibility for evaluating, procuring, and monitoring thrombolytic agents and drug therapy in general. By participating in the development and implementation of treatment guidelines, evaluating economic and therapeutic outcomes, providing timely optimal drug therapy, and educating health care providers and the public, they contribute significantly to the health care team.
Hoag Memorial Hospital, Newport Beach, California, USA.
F L
FL
Meister
K A
KA
Stringer
S A
SA
Spinler
E
E
Gonzalez
R L
RL
Talbert
B
B
Weiner
R M
RM
Guerrero
R
R
Smith
D000277:Adjuvants, Pharmaceutic / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy*; D015912:Thrombolytic Therapy
D000277:Adjuvants, Pharmaceutic; D005343:Fibrinolytic Agents